Ping An Good Doctor and Chugai Pharma China Jointly Establish a Whole Course Management System for Osteoporosis Patients
HONG KONG and SHANGHAI, Dec. 21, 2021 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; Stock Code: 1833.HK) announced that it had entered into a strategic partnership with a leading Japanese pharmaceutical company, Chugai Pharma China Co., Ltd., ("Chugai Pharma China"), to set up an osteoporosis clinic and establish a whole course management system for osteoporosis...
CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER
SUZHOU, China, Dec. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China has approved the new drug application ("NDA") of anti-PD-L1 monoclonal antibody Cejemly® (sugemalimab) in combination with chemotherapy for treatment-naïve metastatic (stage IV) non-small cell lung cancer ("non-small cell lung caner" or "NSCLC") patients....
Huihe Healthcare Completes First K-Clip Treatment in Hong Kong
HONG KONG, Dec. 21, 2021 /PRNewswire/ -- The first successful Transcatheter Tricuspid Annulus repair using a K-Clip has taken place outside of China. The treatment took place on December 19th 2021 at Hong Kong's HK Asia Heart Centre. The treatment is a minimally invasive treatment of mitral and tricuspid valves designed to alleviate symptoms in elderly patients. The patient is...
The Clinician joins AWS ISV Accelerate Program
AUCKLAND, New Zealand, Dec. 21, 2021 /PRNewswire/ -- The Clinician, a global digital health leader, announced today that it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate program. The AWS ISV Accelerate Program is a co-sell program for AWS Partners who provide software solutions that run on or integrate with AWS. The AWS ISV Accelerate...
The New Era Biotechnology Brings The Cooperation Between China And Belarus To A New Level
MINSK, Belarus, Dec. 21, 2021 /PRNewswire/ -- New Era Biotechnology Co., Ltd is an enterprise from the Great Stone China Belarus Industrial Park (CBIP) in Minsk. It participated in the fourth edition of the China International Import Expo (CIIE) which opened in Shanghai on November 5, 2021. Located in Minsk, capital of...
World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine
- Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS ) listed for emergency use by the WHO - EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketed by Serum Institute of India as Covovax™ - EUL by WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility...
European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine
Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 Authorization follows positive recommendation by European Medicines Agency's Committee for Medicinal Products for...
Henlius’ anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population
The ASTRUM-005 states that serplulimab combined with carboplatin-etoposide prolonged median OS in both the overall population and the Asian subgroup, the median overall survival (OS) in the serplulimab and placebo groups were 15.38 and 11.10 months, respectively, reducing risk of death by 38% (41% in the Asian subgroup), p <0.001. The 2-year OS rate (OSR) in the two...
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine
European Commission decision on conditional marketing authorization expected imminently Upon authorization, Nuvaxovid™ (also known as NVX-CoV2373) will be the first protein-based COVID-19 vaccine available in Europe GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization
- New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization - Dr. Andrew Zhu, an internationally renowned oncologist, appointed as President and board director to lead the Company's R&D organization, focusing on global pipeline development - Founder and Chairman Dr. Jingwu Zang named Acting Chief...
